-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Nabriva Therapeutics plc quarterly/annual Earnings Per Share, Diluted history and growth rate from Q1 2015 to Q2 2023.
- Nabriva Therapeutics plc Earnings Per Share, Diluted for the quarter ending June 30, 2023 was -3.73 USD/shares, a 14.8% increase year-over-year.
- Nabriva Therapeutics plc Earnings Per Share, Diluted for the twelve months ending June 30, 2023 was -18.4 USD/shares, a 50.5% increase year-over-year.
- Nabriva Therapeutics plc annual Earnings Per Share, Diluted for 2022 was -21.3 USD/shares, a 25.2% increase from 2021.
- Nabriva Therapeutics plc annual Earnings Per Share, Diluted for 2021 was -28.5 USD/shares, a 78.9% increase from 2020.
- Nabriva Therapeutics plc annual Earnings Per Share, Diluted for 2020 was -135 USD/shares, a 1113% decline from 2019.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)